Comprehensive Guide to Diagnostic Scintigraphy Procedures
Dynamic Kidney Scintigraphy (Scintigrafija Bubreg – Dinamika)
Dynamic kidney scintigraphy is a planar dynamic study employed to evaluate the perfusion, parenchymal function, and excretion phase of the kidneys. The primary radiofarmaceuticals used for this diagnostic procedure include DTPA (pentetate) or MAG3. Depending on specific clinical needs, alternative agents such as or Hippuran, Glucoheptonate (GH), or Ethylendicisteine (EC) may be utilized. The standard administered quantity of the radiofarmaceutical ranges from , which is approximately . In pediatric cases, the dosage is meticulously calculated based on the patient's weight. The radiofarmaceutical is administered via an intravenous (IV) bolus application, often under increased pressure, ensuring that the uptake period begins immediately following the application.
The acquisition duration for a standard study is , with an additional minute reserved for the perfusion method. A Low Energy High Resolution (LEHR) collimator is the standard equipment used. Pregnancy is a strict contraindication for this procedure. Patient preparation is extensive: individuals must be well-hydrated, consuming a minimum of of fluid ( for pediatric patients) within the half-hour preceding the scan. For children, the zoom settings on the equipment must be adjusted according to their size. Patients are instructed to empty their bladder immediately before the procedure begins. Furthermore, if obstructive uropathy is suspected, a diuretic such as Furosemide (Lasix) is administered into the recording at a dose of or (); clinicians must monitor blood pressure closely as this can lead to hypotension.
In cases involving renovascular hypertension caused by renal artery stenosis, a specific Captopril study protocol is followed. Patients take of Captopril orally one hour before the scan, with blood pressure monitored every . The Captopril study itself occurs after a standard dynamic study or within a period. Recording begins either one hour after Captopril administration or once the diastolic pressure has dropped by at least . All relevant prior findings from ultrasound (UZ), X-ray (RTG), CT, and MR should be available. Scanning is typically performed in the Posterior-Anterior (PA) position, except for transplanted kidneys, which are scanned in the Anterior-Posterior (AP) position due to their pelvic placement. Key clinical indications include kidney stones, hydronephrosis (characterized by a lack of curve descent), renal insufficiency, ureteral stenosis or dilatation, and vesicoureteral reflux (VUR) in children.
The dynamic study yields a Region of Interest (ROI) and a renographic curve, facilitating the assessment of the morphology, function, and eliminatory capacity of the ductal system. Note that DTPA reaches its maximum concentration in the renal parenchyma within ; while it is cost-effective, it provides a less detailed curve and is primarily used for glomerular filtration and clearance studies, especially in children under six years of age. In contrast, MAG3 accumulates at rates times higher than DTPA and is preferred for transplant evaluations. Radiofarmaceuticals for dynamic scintigraphy are excreted via the bladder through either glomerular filtration (DTPA) or tubular secretion (MAG3), unlike DMSA which remains in the parenchyma for extended periods. For suspected mobile kidneys, studies may be performed in leavening and then sitting or standing positions with a gap of at least .
Renal Perfusion and Protocol Specifics
The perfusion recording lasts for and is followed by dynamic recordings lasting . The process comprises three distinct phases: the venous phase, the parenchymal phase, and the elimination phase. When integrated into a dynamic study, between images are captured using DTPA or MAG3. If performed as a separate method for suspected perfusion impairment due to arterial narrowing or acute/chronic occlusion, a single image is taken every using Pertechnetate. The full operational protocol includes a static measurement of the full syringe, the dynamic recordings encompassing perfusion, excretion, and a post-void phase (following bladder emptying with a recording), and finally a static measurement of the empty syringe.
Myocardial Scintigraphy (Scintigrafija Miokarda)
Myocardial scintigraphy is a tomographic study utilizing Single Photon Emission Computed Tomography (SPECT) and is conducted in two phases: stress and rest (often involving EKG gating). The primary radiofarmaceutical for both phases is MIBI (containing six isonitrile residues), though Tetrofosmin, Teboroxime, or are used rarely. The dosage for the stress phase is (), while the rest phase requires three times the stress amount. The application is intravenous, with an uptake period of . The rest phase is usually applied approximately after the stress phase. The acquisition duration is precisely , utilizing a LEHR collimator. Pregnancy is a general contraindication.
Preparation for myocardial scintigraphy requires the patient to fast for prior to the exam, allowing only water. Diabetic patients may have a light breakfast with their therapy before the exam. Crucially, beta-blockers and other relevant medications must be discontinued prior, and caffeine must also be excluded for before pharmacological stress tests. Blood pressure must be regulated before mechanical exertion. For the stress phase, patients consume water after the radiofarmaceutical application. The scanning process involves two detectors positioned at a angle, rotating every , while the patient lies on the table with arms raised above the head and feet toward the machine.
Indications for this study include verifying or excluding unconfirmed coronary artery disease and evaluating verified coronary disease, such as post-infarction assessments for "frozen" or viable myocardium. In cases where the heart is in a resting phase following a heart attack, Nitrolingual spray may be administered prior to the radiofarmaceutical to relax the arteries. Protocols can span one or two days, always comparing stress and rest phases to identify reversible ischemic changes or myocardial scarring. The rest phase specifically measures ejection fraction and viability. Stress can be induced mechanically (ergometry, bicycle) or pharmacologically (Adenosine, Dobutamine, Regadenoson), with the latter indicated for severe heart patients or those with mobility issues such as paraplegics. The gSPECT method tracks heart function by calculating the End-Systolic Volume (ESV) and End-Diastolic Volume (EDV) to determine the ejection fraction. Planar methods are avoided due to radiofarmaceutical accumulation in the liver and intestines, which can overlap with the myocardial signal.
Comparative findings are interpreted as follows: if both stress and rest are normal, the result is normal. If there is a perfusion deficit during stress but the rest phase is normal, it indicates ischemia. If perfusion deficits are present in both stress and rest, it signifies a scar. Finally, a stress perfusion deficit combined with an incomplete rest deficit indicates ischemia within a scar.
Parathyroid Gland Scintigraphy (Scintigrafija Paratireoidnih Űlijezda)
This is primarily a planar static study, though tomographic (SPECT), whole-body (WB), and hybrid studies may be performed. The radiofarmaceuticals used are MIBI or Tetrofosmin, and occasionally Chloride or Pertechnetate. The standard dose is () administered intravenously. The procedure involves a dual-stage uptake: early statics at and late statics (washout), tomographic, or hybrid imaging at . Acquisition takes for early images and for late images using a LEHR collimator. There is no special patient preparation other than bringing ultrasound findings and Parathyroid Hormone (PTH) levels. The scan is performed in the AP position with the head tilted slightly back. Indications include adenoma, hyperplasia, and carcinoma.
Two methods exist: subtraction and sequential. The subtraction method, though rare, involves using Pertechnetate and or MIBI. A computer program subtracts the thyroid signal (from Pertechnetate) from the combined thyroid/parathyroid signal (from or MIBI). The subtraction protocol involves an IV injection of () Pertechnetate followed by dynamic imaging after . Then, () of or of MIBI is injected, with further dynamic imaging after . The sequential method uses of MIBI; early statics at show both the thyroid and parathyroid glands, while late statics at highlight parathyroid changes. If a change is seen on an additional static image an hour after the late scan, it confirms an adenoma, as the thyroid should have washed out. It is advised to avoid including the mediastinum to prevent visualization of the aortic arch.
Bone Scintigraphy (Scintigrafija Skeleta)
Bone scintigraphy involves whole-body (WB) imaging, often supplemented by SPECT, SPECT/CT (hybrid), or additional static images. The radiofarmaceuticals used are diphosphonates (pyrophosphate analogs) like MDP, HDP, or DPD. The dose is (), while children receive per of weight. Following IV application, there is an uptake period of . WB acquisition (AP and PA) takes , while tomographic methods take using a LEHR collimator. Patients are encouraged to eat and drink normally but should consume of fluid after injection and empty their bladder before scanning. Dual-head gamma cameras capture images from the head to the mid-femur. Indications include primary bone tumors, metastatic disease, osteomyelitis, metabolic bone diseases like osteoporosis, fractures, aseptic necrosis, Paget's disease, and suspected prosthesis rejection.
The procedure often includes three-phase bone scintigraphy. The first phase is the vascular phase, a dynamic planar acquisition lasting that starts immediately after bolus injection to show blood flow in the target region. The second phase, the early static (blood pool) scintigram, lasts and is performed after the vascular phase to show distribution in the vascular spaces. The third phase consists of late static images taken after application, lasting . It is generally recommended to perform a whole-body scan after completing the three-phase protocol.
Meckel's Diverticulum Scintigraphy
This is a planar dynamic method, sometimes supplemented by static imaging, used primarily to visualize ectopic gastric mucosa. The radiofarmaceutical of choice is Pertechnetate, administered in doses of () intravenously. In pediatric cases, a minimum dose of is used. The uptake period begins immediately. Acquisition ideally lasts , though it can range from . Patients must fast for and wait at least after any barium swallow tests. The bladder must be emptied immediately before scanning in the AP position. Clinical indications include rectal bleeding, anemia, and abdominal pain.
Hepatobiliary Scintigraphy
This planar dynamic study assesses the function and morphology of the liver and biliary tract using HIDA ( or ). The radiofarmaceutical is excreted via hepatocytes into the bile and eventually the duodenum, with only excreted through the kidneys. Patients must fast for . For infants, phenobarbital () is given for prior to differentiate neonatal hepatitis from biliary atresia. Morphine () may be used to accelerate gallbladder visualization by contracting the Sphincter of Oddi, or Cholecystokinin (CCK) may be administered. Scanning occurs in the AP position over four phases: the vascular phase (), the renal phase () where liver activity peaks, the parenchymal phase () showing bile ducts, and the intestinal phase (). Total acquisition involves a dynamic scan, followed by a static and potentially a static within . Indications include biliary calculi, jaundice differentiation, cholecystitis, and biliary obstruction.
Lung Scintigraphy (Scintigrafija Pluća)
Lung scintigraphy involves two phases: ventilation and perfusion. It is typically a SPECT study, though planar statics are possible. For ventilation, radioactive aerosoles labeled with Pertechnetate (or "Technegas" using breaths) are used at a dose of . For perfusion, MAA (particle size ) or HAM is injected at ( for pregnant women). Recording for ventilation takes and perfusion takes . Patients should be well-hydrated ( fluid). Perfusion radiofarmaceuticals should be applied while the patient is lying down and breathing deeply to ensure even distribution between apical and basal sections. Indications include pulmonary embolism, obstructive/restrictive diseases, and tumors. Findings are interpreted via V/Q matching (matching ventilation and perfusion deficits) or V/Q mismatching (indicative of pulmonary embolism).
Lymphoscintigraphy and Sentinel Lymph Node (SLN)
Lymphoscintigraphy uses Nanocolloid administered subcutaneously to evaluate lymphedema. For Sentinel Lymph Node (SLN) detection, often used for breast cancer, thyroid, or colon cancer, the dose is lower (). SLN application can be peritumoral, subdermal, intradermal, or intratumoral. In limb studies, the tracer is injected between the first and second digits. Physical activity or massage helps lymph flow. For SLN, the syringe volume is . The SLN is the first node on the path from the tumor; multiple can exist. Sites are marked with a cobalt marker and detected using a gamma probe. Acquisition for SLN is typically per frame.
Brain Scintigraphy (Scintigrafija Mozga)
This multifaceted study can involve planar dynamics, statics, SPECT/CT, PET/CT, or daTSCAN. Specific radiofarmaceuticals include Pertechnetate for perfusion, while HMPAO and ECD are standard for brain death and regional blood flow. Ioflupane is used for daTSCAN. Dosages vary: for daTSCAN, for perfusion, and for brain death. Preparation may include sodium perchlorate or Lugol’s solution to block the thyroid and choroid plexus. Potassium iodide () is another option.
In brain death scintigraphy ( sensitivity via SPECT), dynamic recording begins immediately, followed by early statics at and delayed statics at . A "hot nose" sign (nasal accumulation) is noted but not specific to brain activity. Perfusion scintigraphy tracks the first of bolus passage through the carotids. For Parkinson's disease (daTSCAN), the state of the presynaptic and postsynaptic dopamine synapses (receptors and ) is evaluated after a injection. Proper head positioning is vital for accuracy.
Somatostatin Receptor Scintigraphy
Used primarily for neuroendocrine tumors (NET), this study utilizes Tecrotyde/Octreotide or at a dose of . The uptake period has two segments: and post-application. WB scans and directed statics of the thorax/abdomen () are required at both intervals, with SPECT/CT of the thorax/abdomen/pelvis performed at . Somatostatin typically accumulates in the liver, spleen, and small intestine. NET patients treated with Sandostatin must wait before scintigraphy. Chromogranin (CHR) is the tumor marker for NETs. High receptor expression results in better image quality but indicates a poorer prognosis. For PET, DOPA, DOTATOC, or DOTATE are used depending on the somatostatin receptor type.
Testicular Scintigraphy (Scintigrafija Testisa)
This planar dynamic and static study uses Pertechnetate () via high-pressure IV bolus. Patients have their penis taped to the abdomen and testicles separated to avoid superposition. A marker is used to center the testicles in the field of view and mark one side for identification. The recording captures the initial vascular pass (angiogram), followed by a blood-pool static and a tissue phase. Indications include testicular torsion, epididymitis, infarcts, or hydrocele.
Thyroid and Static Kidney Scintigraphy
Thyroid scintigraphy uses Pertechnetate () with an uptake period of . Pinhole or LEHR collimators are used in the AP position. Patients must pause hypothyroidism medications (Letrox, Euthyrox) for . "Cold nodes" (non-accumulating) represent cysts, fibrosis, or potentially carcinoma ( chance), while "hot nodes" are generally benign.
Static kidney scintigraphy utilizes DMSA (), which consists of two carbon and two thiol groups. It has a long uptake period of . It is specifically used to detect cortical scarring from pyelonephritis and evaluate kidney size and position. The radiofarmaceutical is light-sensitive and must be used immediately after synthesis. Scanning is primarily in the PA position with extra projections like AP or lateral as needed.